Accessibility Menu
Hansoh Pharmaceutical Group logo

Hansoh Pharmaceutical Group(SEHK) 3692

Market CapHK$203.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+82%
5 Year+16%
1 Year-11%
1 Month+9%
HK$32.12
-0.68%
-0.22Today
Hansoh Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 32.342026-07-30
Hansoh Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.74%HKD 32.582026-07-23
1 month+9.18%HKD 29.622026-06-30
3 month-12.83%HKD 37.102026-04-30
Year to date-10.37%HKD 36.082025-12-31
1 year-11.15%HKD 36.402025-07-30
3 year+156.67%HKD 12.602023-07-31
5 year+16.12%HKD 27.852021-07-30
Since inception+82.44%HKD 18.372019-06-14

Hansoh Pharmaceutical Group Financials at a Glance

Market Cap

HK$203.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥27.29B

Net Income (TTM)

CN¥9.93B

EPS (TTM)

HK$1.01

P/E Ratio

33.22

Dividend

HK$0.43

Beta (Volatility)

-0.04 (Low)

Price

HK$32.12

Volume

5,435,412

Open

HK$32.74

Previous Close

HK$32.34

Daily Range

HK$31.80 - HK$32.74

52-Week Range

HK$28.06 - HK$44.22

Estimated Earnings Date

Aug 20, 2026

3692 News

Pharmacists reviewing medication

5 Best GLP-1 Stocks for 2026 and How to Invest

Rachel WarrenJun 24, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hansoh Pharmaceutical Group

Hansoh Pharmaceutical Group Company Limited is a leading pharmaceutical company based in China, specializing in the research, development, production, and sale of innovative drugs. The company focuses on therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases, aiming to improve patient outcomes through advanced medical solutions.

Products and Services
  • Offers a diverse range of pharmaceutical products for various therapeutic areas
  • Key products include Ameile, Hansoh Xinfu, and Pulaile
  • Engages in strategic partnerships for drug development with global pharmaceutical companies
Growth Outlook
  • Revenue increased to CNY 7.59 billion in Q4 2025, reflecting strong market demand
  • Net income reached CNY 2.42 billion in Q4 2025, showcasing robust profitability
  • Strategic collaborations with global firms enhance product pipeline and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 28.5 billion, indicating consistent growth
  • Operating profit margin of 29.77% in Q4 2025, demonstrating operational efficiency
  • Strong cash flow with free cash flow of CNY 3.77 billion in Q4 2025
Hansoh Pharmaceutical Group Company Limited has established itself as a key player in the pharmaceutical industry, particularly within China. The company's commitment to research and development is evident in its diverse product offerings and strategic partnerships, which are designed to enhance its competitive edge. Recent financial performance highlights a strong revenue trajectory and profitability, positioning the company favorably for future growth. With a focus on innovative therapies and expanding market presence, Hansoh Pharmaceutical is well-positioned to capitalize on the growing demand for healthcare solutions in the region.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,347

CEO

Hui Juan Zhong, EMBA

Website

www.hspharm.com

Headquarters

Shanghai, SH 201210, CN

3692 Financials

Key Financial Metrics (TTM)

Gross Margin

89.89%

Operating Margin

36.04%

Net Income Margin

36.97%

Return on Equity

16.71%

Return on Capital

15.26%

Return on Assets

13.92%

Earnings Yield

3.01%

Dividend Yield

1.29%

Payout Ratio

36.22%

Stock Overview

Market Cap

HK$203.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.06B

Volume

5.44M

Avg. Volume

11.66M

Financials (TTM)

Gross Profit

CN¥24.65B

Operating Income

CN¥9.37B

EBITDA

CN¥10.02B

Operating Cash Flow

CN¥12.12B

Capital Expenditure

-CN¥591.41M

Free Cash Flow

CN¥11.52B

Cash & ST Invst.

CN¥31.58B

Total Debt

CN¥105.14M

Hansoh Pharmaceutical Group Performance Analysis

Hansoh Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 10,910,600,033-8.9%
20232023-12-31CNY 11,164,685,3942.3%
20242024-12-31CNY 13,293,466,86719.1%
20252025-12-31CNY 16,298,568,60122.6%
Hansoh Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3016.3%
Q42024-12-31-11.5%
Q22025-06-3029.2%
Q42025-12-312.2%
Hansoh Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.51-5.0%
20232023-12-31CNY 0.6018.7%
20242024-12-31CNY 0.8032.4%
20252025-12-31CNY 1.0126.5%
Hansoh Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3039.4%
Q42024-12-31-39.1%
Q22025-06-3089.3%
Q42025-12-31-24.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥7.59B

+35.8%

Gross Profit

CN¥6.75B

+32.6%

Gross Margin

88.92%

N/A

Market Cap

HK$203.23BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$21.74M

N/A

Employees

9,347

N/A

Net Income

CN¥2.42B

+21.7%

EBITDA

CN¥2.43B

+34.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥31.58B

+27.0%

Total Debt

CN¥105.14M

-97.6%

Accounts Receivable

CN¥3.06B

-4.7%

Inventory

CN¥609.18M

+5.8%

Long Term Debt

CN¥47.64M

-54.4%

Short Term Debt

CN¥57.47M

-98.6%

Return on Assets

13.92%

N/A

Return on Invested Capital

15.25%

N/A

Free Cash Flow

CN¥3.77B

+104.6%

Operating Cash Flow

CN¥3.95B

+100.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,428.32+0.02%
^DJIDJI
$52,162.48+0.01%
^IXICNASDAQ
$25,071.39+0.03%
BTCBitcoin
$64,736.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About 3692

What is the current price of Hansoh Pharmaceutical Group?

Hansoh Pharmaceutical Group is trading at HK$32.12 per share.

What is the 52-week range for Hansoh Pharmaceutical Group?

Over the past 52 weeks, Hansoh Pharmaceutical Group has traded between HK$28.06 and HK$44.22.

How much debt does Hansoh Pharmaceutical Group have?

As of the most recent reporting period, Hansoh Pharmaceutical Group reported total debt of CN¥117.05M.

How much cash does Hansoh Pharmaceutical Group have on hand?

Hansoh Pharmaceutical Group reported CN¥3.80B in cash and cash equivalents in its most recent financial results.

What is Hansoh Pharmaceutical Group’s dividend yield?

Hansoh Pharmaceutical Group currently has a dividend yield of 1.29%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services